课题基金 / 基金详情

Using solubel peptide-MHC tetramer, the trial of staining and cloning the melanoma antigen-specific cytotoxic lymphocytes

Using solubel peptide-MHC tetramer, the trial of staining and cloning the melanoma antigen-specific cytotoxic lymphocytes
利用可溶性肽-MHC四聚体染色和克隆黑色素瘤抗原特异性细胞毒性淋巴细胞的试验
批准号:
11670849
负责人:
SAKURAI Toshiharu
金额:
$2.43万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1999
资助国家:
日本
项目状态:
已结题
起止时间:
1999 至 2000

项目摘要

项目成果

SAKURAI Toshiharu的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The purpose of this project is to construct the soluble class I MHC-peptide complex ("tetramers") and to visualize the melanoma antigen-specific cytotoxic lymphocytes (CTL) using the produced tetramers.1. We have produced HLA-A2/gp100_<(209-217)>, HLA-A2/MART-1_<(27-35)>, and HLA-A24/EBV-P tetramers. The β2-microglobulin (β2m) and soluble HLA-A2 and A24 heavy chains linked at its carboxyl terminus to a BirA substrate peptide were expressed separately in Escherichia coli. The expressed HLA-A2 or A24-BirA substrate peptide and β2m subunits were refolded together in vitro in the presence of synthetic antigenic peptides, corresponding to the HLA-A2-restricted melanoma-immunogenic epitopes of gp100_<(209-217)> (ITDQVPFSV) and MART-1_<(27-35)> (AAGIGILTV), and HLA-A24 restricted viral-immunogenic epitope of EBV-P (TYGPVFMCL). Folded materials were then subjected to enzymatic biotinylation with BirA enzyme. The HLA-A2 or A24/peptide complexes were purified first on a get filtration column and … More subsequently on a Mono Q ion exchange column. Tetrameric complexes of the biotinylated HLA-A2 or A24/peptide were finally produced by mixing the purified biotinylated heterodimers with Streptavidine-phycoerythrin (PE) conjugates at a molar ratio of 4 : 1.2. The specific binding of the HLA-A2/gp100_<(209-217)> and HLA-A2/MART-1_<(27-35)> tetramers were assessed by staining the relevant peptide-specific tumor-infiltrating T-lymphocytes (TILs), TIL1520 and TIL1235 respectively, and analyzing them on flow cytometry. The HLA-A2/gp100_<(209-217)> tetramer specifically stained more than 90% of TIL1520 specific for the gp100_<(209-217)> peptide, but, did not stain TIL1370 specific for irrelevant gp100_<(154-162)> (G154 : KTWGQYWQV) peptide. In addition, using HLA-A24/EBV-P tetramer, we have analyzed EBV-P specific CTL that was generated by in vitro stimulation with the peptide from peripheral blood mononuclear cells (PBMCs) of HLA-A24 healthy donor and the CTL were found to stain with the tetramer.These results indicate that the produced peptide-MHC tetramers can be used to specifically bind to antigen-specific CTL restricted by both HLA-A2 and HLA-A24, and possibly to enrich specific CTL among a heterogeneous population. Less
期刊论文(16)
专著(0)
科研奖励(0)
会议论文
YUTAKA KAWAKAMI: "Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma"Journal of Immunotherapy. 23. 17-27 (2000)
YUTAKA KAWAKAMI:“来自 123 名黑色素瘤患者的肿瘤浸润 T 淋巴细胞对与主要 HLA-A 等位基因相关的共有黑色素瘤抗原的识别”《免疫治疗杂志》。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Y.Kawakami, X.Wang, T.Shofuda, H.Suminoto, J.P.Tupesis, E.Fitzgerald, and S.A.Rosenberg.: "Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor infiltrating T lymphocytes."J Immunology. 166. 2871-2877 (2
Y.Kawakami、X.Wang、T.Shofuda、H.Suminoto、J.P.Tupesis、E.Fitzgerald 和 S.A.Rosenberg.:“分离出一种新的黑色素瘤抗原 MART-2,其中含有可被自体肿瘤浸润 T 识别的突变表位
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Kawakami, Y.: "Development of new immunotherapy using cancer antigens recognized by Tlymphocytes."New Strategy for Cancer Treatment, Proceedings of the 3rd Shizuoka Forum on Health and Longevity. 62-68 (2000)
Kawakami, Y.:“利用 T 淋巴细胞识别的癌症抗原开发新的免疫疗法。”癌症治疗新策略,第三届静冈健康与长寿论坛论文集。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Coulie PG: "Antitumor immunity at work in a melanoma"Advances in Cancer Research. 76. 213-242 (1999)
Coulie PG:“抗肿瘤免疫在黑色素瘤中发挥作用”癌症研究进展。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
14
    Molecular link between stress response and cancer and its clinical implication
    • 批准号:
      17K09396
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.0万
    • 财政年份:
      2017
    • 负责人:
      SAKURAI Toshiharu
    • 依托单位:
    Novel molecular target in colorectal cancer and inflammatory bowel disease
    • 批准号:
      26460979
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.08万
    • 财政年份:
      2014
    • 负责人:
      SAKURAI Toshiharu
    • 依托单位:
    Translational research focusing on the regulation of proteasome by Gankyrin
    • 批准号:
      23590998
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.33万
    • 财政年份:
      2011
    • 负责人:
      SAKURAI Toshiharu
    • 依托单位:
    Elucidation of the resistance mechanisms of immunotherapy by the abnormal signal transduction in melanoma and development of methods to overcome it
    • 批准号:
      21591445
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.91万
    • 财政年份:
      2009
    • 负责人:
      SAKURAI Toshiharu
    • 依托单位:
    国内基金
    海外基金
    特异识别ALDH1A1的HLA-A2限制性CTL 联合SHH抑制剂杀伤胰腺癌干细胞的机制研究
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2022
    • 负责人:
      蔡磊
    • 依托单位:
    HLA-A2抗体通过Src-钙信号通路诱发TRALI的作用及相关机制研究
    • 批准号:
      81760381
    • 项目类别:
      地区科学基金项目
    • 资助金额:
      32.0万元
    • 批准年份:
      2017
    • 负责人:
      乐爱平
    • 依托单位:
    HLA-A2限制性食管癌特异性突变抗原CTL新表位的鉴定和免疫活性研究
    • 批准号:
      81601448
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      18.0万元
    • 批准年份:
      2016
    • 负责人:
      吴亚红
    • 依托单位:
    汉滩病毒糖蛋白HLA-A2限制性CTL表位免疫保护性作用的评价